Cited by 154Hepatocellular Carcinoma Treatment and PrognosisOrgan Transplantation Techniques and OutcomesRenal cell carcinoma treatment

Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium

Open access
Mehta, Neil, Frenette, Catherine, Tabrizian, Parissa, Hoteit, Maarouf, Guy, Jennifer, Parikh, Neehar, Ghaziani, T. Tara, Dhanasekaran, Renu +8 more·2021·Gastroenterology

Abstract

Background & aims United Network of Organ Sharing (UNOS) has adopted uniform criteria for downstaging (UNOS-DS) of hepatocellular carcinoma (HCC) before liver transplantation (LT), but the downstaging success rate and intention-to-treat outcomes across broad geographic regions are unknown.Methods In this first multiregional study (7 centers, 4 UNOS regions), 209 consecutive patients with HCC undergoing downstaging based on UNOS-DS criteria were prospectively evaluated from 2016 to 2019.Results Probability of successful downstaging to Milan criteria and dropout at 2 years from the initial downstaging procedure was 87.7% and 37.3%, respectively. Pretreatment with lectin-reactive α-fetoprotein ≥10% (hazard ratio, 3.7; P = .02) was associated with increased dropout risk. When chemoembolization (n = 132) and yttrium-90 radioembolization (n = 62) were compared as the initial downstaging treatment, there were no differences in Modified Response Evaluation Criteria In Solid Tumors response, probability of or time to successful downstaging, waiting list dropout, or LT. Probability of LT at 3 years was 46.6% after a median of 17.2 months. In the explant, 17.5% had vascular invasion, and 42.8% exceeded Milan criteria (understaging). The only factor associated with understaging was the sum of the number of lesions plus largest tumor diameter on the last pre-LT imaging, and the odds of understaging increased by 35% per 1-unit increase in this sum. Post-LT survival at 2 years was 95%, and HCC recurrence occurred in 7.9%.Conclusion In this first prospective multiregional study based on UNOS-DS criteria, we observed a successful downstaging rate of >80% and similar efficacy of chemoembolization and yttrium-90 radioembolization as the initial downstaging treatment. A high rate of tumor understaging was observed despite excellent 2-year post-LT survival of 95%. Additional LRT to reduce viable tumor burden may reduce tumor understaging.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1053/j.gastro.2021.07.033

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 40 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Mehta, N., Frenette, C., Tabrizian, P., Hoteit, M., Guy, J., Parikh, N., Ghaziani, T. T., Dhanasekaran, R., Dodge, J. L., Natarajan, B., Holzner, M. L., Frankul, L., Chan, W., Fobar, A., Florman, S., & Yao, F. Y.
Affiliations
  • University of California, San Francisco (US)
  • Scripps Green Hospital (US)
  • Icahn School of Medicine at Mount Sinai (US)
  • University of Pennsylvania (US)
  • California Pacific Medical Center (US)
  • University of Michigan (US)
  • Stanford University (US)
Corresponding author
Mehta, Neil
Venue
Gastroenterology
Publisher
Elsevier BV
Published
2021-11
Volume
161
Issue
5
Pages
1502-1512
ISSN
0016-5085 (ISSN-L)
OpenAlex
W3184850586
Cited by
154
References
40
Citations by year
2026: 25 · 2025: 29 · 2024: 42 · 2023: 33 · 2022: 20 · 2021: 3
FWCI
13.61
Type
journal article
Language
en
Open access
Locations
  • Gastroenterology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • Exelixis
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • Liver Center, University of California, San Francisco
  • Eli Lilly and Company
  • Bayer Fund
  • Eisai
  • National Institutes of Health (P30 DK026743)
  • Genentech
Topics
  • Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
  • Health Sciences › Medicine › Surgery › Organ Transplantation Techniques and Outcomes
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Renal cell carcinoma treatment
Keywords
hepatocellular carcinoma, tumor downstaging, liver transplantation, Milan criteria, understaging, transarterial chemoembolization, yttrium-90 radioembolization, alpha-fetoprotein, tumor size, HCC recurrence, post-transplant survival, vascular invasion
MeSH terms
Aged, Feasibility Studies, Female, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Male, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Patient Dropouts, Prospective Studies, Risk Factors, Time Factors, United States, Waiting Lists, Liver Transplantation, Chemoembolization, Therapeutic, Treatment Outcome, Disease Progression, Risk Assessment, Radiopharmaceuticals, Tumor Burden

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review